This wiki showcases the 2024 Oklahoma State University iGEM project, Healios. Our approach merges photodynamic light therapy with an engineered M13 bacteriophage that specifically targets Staphylococcus aureus, allowing for the destruction of the pathogen upon exposure to light. The engineered phage is conjugated to rose bengal, a photosensitizer. When the phage binds to S. aureus cells, and is exposed to green or blue light, it activates the rose bengal dye that generates reactive oxygen species, leading to localized damage at the attachment site of the phage. We focus on S. aureus due to its rising prevalence as a leading cause of infections, from minor skin issues to severe bloodstream infections, and its ability to develop resistance to multiple antibiotics, particularly MRSA. As traditional treatments struggle with antibiotic resistance, our project aims to combat this significant public health threat by developing effective treatment and prevention strategies against S. aureus infections. We chose the M13 bacteriophage because it is a safe and flexible platform that can be easily genetically modified to enhance targeting and delivery of therapeutic agents. To facilitate this, our helper-phage/production plasmid system is designed to enable other researchers to easily adapt our technology to retarget M13 toward any bacterial pathogen of choice.